JUBEREQ (denosumab-desu) 120 mg/1.7 mL injection, for subcutaneous use
JUBEREQ is an FDA-approved interchangeable biosimilar and offers identical dosing and administration as XGEVA.1,2
Not an actual patient
JUBEREQ (denosumab-desu) 120 mg/1.7 mL injection, for subcutaneous use
JUBEREQ is an FDA-approved interchangeable biosimilar and offers identical dosing and administration as XGEVA.1,2
When ready to start or switch to JUBEREQ
See below for the coding and billing information you’ll need when JUBEREQ becomes commercially available.
| Coding | Description |
|---|---|
| Q-Code: Q5166 | Injection, denosumab-desu (JUBEREQ), biosimilar, 1 mg |
| Administration CPT® Code: 96XXX | Determine appropriate product administration CPT code |
| JW/JZ Modifier | JW Modifier: Drug amount discarded/not administered to any patient OR JZ Modifier: No discarded amounts |
| TB Modifier | CMS requires all 340B-covered entities to report the TB modifier on claims |
| Billable Units | Description |
| 1 milligram = 1 billing unit | JUBEREQ dose = 120 milligrams |
| NDC | Description |
| 69448-022-63 (10 digit) 69448-0022-63 (11 digit) | 120 mg/1.7 mL (70 mg/mL) single-dose vial |
CMS, Centers for Medicare & Medicaid Services; CPT, Current Procedural Terminology; NDC, National Drug Code.
JUBEREQ has the same Medicare Part B* reimbursement as XGEVA.
Medicare Part B represents 33% of denosumabs with the same indications as JUBEREQ.3
No step therapy edits
No prior authorization needed
*Coverage and prior authorization requirements may vary by payer. This content is provided for informational purposes only. Accord BioPharma, Inc. does not guarantee coverage or reimbursement for JUBEREQ. It is the sole responsibility of healthcare professionals to ensure the reported codes are accurate, complete, and supported by medical record documentation.
JUBEREQ is covered on the following plans†
| Insurance Plan | Coverage Type |
|---|---|
| Medicare | Part B Fee-for-Service (FFS), effective 7/1/26 |
| Cigna | 1-of-3 preferred on the Advantage, Performance, and Legacy Performance commercial pharmacy benefit drug lists, effective 7/1/26 |
| Cigna | 1-of-3 preferred on the commercial medical benefit, effective 9/1/26 |
†Coverage for JUBEREQ varies by insurance plan. Regarding the availability of JUBEREQ on your patient’s plan, please refer to their specific local insurance coverage policy requirements. We will update this website when new JUBEREQ coverage information is available.
Comprehensive support for the patient care journey
$0
co-pay per JUBEREQ treatment
For eligible patients
Co-Pay Program
Reduce out-of-pocket expenses
AccordCares® offers a co-pay program‡ for eligible patients with commercial insurance that covers out-of-pocket expenses related to
Eligible patients may pay as little as $0 co-pay per JUBEREQ treatment.
Terms and Conditions may apply.
‡Co-pay program will be activated in July 2026, once JUBEREQ is available.
Not an actual patient
Register your appropriate patients through AccordCares, and commercially insured eligible patients can start on JUBEREQ with a $0 co-pay.
Even if your practice has its own system for benefits reimbursement and prior authorizations, you can still use AccordCares to provide patients with a $0 co-pay.
Other key offerings include
Benefits Investigation
Prior Authorization Support
Billing and Coding Information
Alternate Funding Referral
AccordCares Enrollment Form
For assistance, please call AccordCares at
1-866-258-7151.
Monday through Friday, 8 AM to 8 PM ET | AccordCares.com
Accord BioPharma
Accord BioPharma is a US-based company focused on biosimilars and specialty
pharmaceuticals that include oncology, immunology, and urology therapies.
20
by 2030
Global Biosimilar Leader
Accord’s parent company has more than 2 decades of experience, with products sold in 85+ countries.
Accord is preparing a portfolio of
20 biosimilars by 2030.
Current portfolio of
7 FDA-approved therapies.
Accord has one of the largest biosimilar
pipelines, with 10 in oncology.